Elite Pharmaceuticals(ELTP)
$0.32-0.03 (-9.78%)
ELTP
Elite Pharmaceuticals financials statements
$0.32
At close:-0.03 (-9.78%)
Want to see ELTP full AI Analyst Report?
Elite Pharmaceuticals (ELTP) Ratios
378 Followers
Elite Pharmaceuticals Ratios
ELTP's free cash flow for Q2 2027 was $-3.81M. For the 2027 fiscal year, ELTP's free cash flow was decreased by $-732.18K and operating cash flow was $-3.07M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Jun 25 | Jun 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.45 | 4.88 | 3.07 | 2.75 | 2.82 |
| Quick Ratio | -1215.99 | 3.50 | 2.08 | 1.53 | 1.81 |
| Cash Ratio | 1713.36 | 0.96 | 0.54 | 1.00 | 1.28 |
| Solvency Ratio | 1.19 | -0.05 | 0.83 | 369.58 | 1.04 |
| Operating Cash Flow Ratio | 1365.50 | 0.63 | -0.25 | 0.43 | 0.97 |
| Short-Term Operating Cash Flow Coverage | 103886.74 | 1.76 | -0.76 | 10.74 | 18.39 |
| Net Current Asset Value | $ 72.70M | $ 14.87M | $ 13.94M | $ 9.57M | $ 8.93M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.11 | 0.14 | 0.10 | 0.08 |
| Debt-to-Equity Ratio | 0.06 | 0.20 | 0.20 | 0.13 | 0.11 |
| Debt-to-Capital Ratio | 0.06 | 0.17 | 0.17 | 0.12 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.05 | 0.05 | 0.11 | 0.05 |
| Financial Leverage Ratio | 1.40 | 1.80 | 1.45 | 1.41 | 1.39 |
| Debt Service Coverage Ratio | 64.03 | -0.28 | 4.54 | 302.38 | 15.08 |
| Interest Coverage Ratio | 125.95 | 25.38 | 18.33 | 1819.99 | 26.44 |
| Debt to Market Cap | 0.01 | 0.02 | 0.05 | 0.13 | 0.05 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Net Debt to EBITDA | -573.16 | -0.14 | 1.84 | -0.61 | -0.89 |
| Profitability Margins | |||||
| Gross Profit Margin | 49.36% | 47.70% | 46.55% | 48.58% | 45.86% |
| EBIT Margin | 33.56% | 0.86% | 1.86% | 0.01% | 15.72% |
| EBITDA Margin | 34.92% | 3.38% | 4.46% | 0.02% | 20.12% |
| Operating Profit Margin | 33.56% | 23.32% | 19.05% | 5.93% | 15.72% |
| Pretax Profit Margin | 38.16% | -0.06% | 0.82% | 11.67% | 22.20% |
| Net Profit Margin | 30.14% | -5.13% | 35.51% | 12.91% | 27.58% |
| Continuous Operations Profit Margin | 30.14% | -5.13% | 35.51% | 0.01% | 27.58% |
| Net Income Per EBT | 78.98% | 8275.14% | 4342.25% | 110.64% | 124.25% |
| EBT Per EBIT | 113.72% | -0.27% | 4.29% | 196.82% | 141.24% |
| Return on Assets (ROA) | 32.45% | -4.48% | 24.04% | 10783.21% | 25.32% |
| Return on Equity (ROE) | 45.38% | -8.06% | 34.92% | 15227.43% | 35.28% |
| Return on Capital Employed (ROCE) | 41.32% | 23.18% | 15.28% | 6125.12% | 17.82% |
| Return on Invested Capital (ROIC) | 32.33% | 21.87% | 14.27% | 6065.36% | 17.48% |
| Return on Tangible Assets | -0.96% | -4.75% | 26.01% | 12762.06% | 31.21% |
| Earnings Yield | 11.54% | -0.93% | 12.94% | 15012.72% | 25.19% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.49 | 2.88 | 2.91 | 11037.19 | 10.55 |
| Payables Turnover | 12.45 | 14.86 | 11.15 | 7177.14 | 12.21 |
| Inventory Turnover | 0.00 | 2.71 | 2.34 | 1838.72 | 2.59 |
| Fixed Asset Turnover | 0.01 | 5.96 | 3.88 | 3271.81 | 4.62 |
| Asset Turnover | 1.08 | 0.87 | 0.68 | 835.17 | 0.92 |
| Working Capital Turnover Ratio | 2.12 | 2.31 | 2.79 | 2643.20 | 3.48 |
| Cash Conversion Cycle | 103041.71 | 237.14 | 248.59 | 0.18 | 145.56 |
| Days of Sales Outstanding | 146.41 | 126.85 | 125.39 | 0.03 | 34.60 |
| Days of Inventory Outstanding | 102924.61 | 134.85 | 155.93 | 0.20 | 140.87 |
| Days of Payables Outstanding | 29.31 | 24.56 | 32.73 | 0.05 | 29.90 |
| Operating Cycle | 103071.02 | 261.70 | 281.32 | 0.23 | 175.47 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 22.14 | 0.01 | -0.00 | 0.00 | 0.01 |
| Free Cash Flow Per Share | 21.27 | 0.00 | -0.00 | -0.00 | 0.01 |
| Dividend Paid and CapEx Coverage Ratio | 25.66 | 2.95 | -4.05 | 0.58 | 13.05 |
| Capital Expenditure Coverage Ratio | 25.66 | 2.95 | -4.05 | 0.58 | 13.05 |
| Operating Cash Flow Coverage Ratio | 4083.51 | 0.68 | -0.28 | 0.86 | 2.34 |
| Operating Cash Flow to Sales Ratio | 159.52 | 0.09 | -0.06 | 0.00 | 0.20 |
| Free Cash Flow Yield | 5870.03% | 1.06% | -2.63% | -8.16% | 17.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 8.67 | -108.75 | 7.73 | 0.01 | 3.97 |
| Price-to-Sales (P/S) Ratio | 2.61 | 5.53 | 2.74 | 0.00 | 1.09 |
| Price-to-Book (P/B) Ratio | 3.93 | 8.68 | 2.70 | 1.01 | 1.40 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.02 | 94.25 | -37.97 | -12.25 | 5.88 |
| Price-to-Operating Cash Flow Ratio | 0.02 | 62.33 | -47.34 | 8.80 | 5.43 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.90 | -0.08 | 0.00 | 0.06 |
| Enterprise Value Multiple | -565.68 | 163.34 | 63.41 | 3.96 | 4.55 |
| Enterprise Value | -29.40B | 464.31M | 159.99M | 25.43M | 29.57M |
| EV to EBITDA | -565.68 | 163.34 | 63.41 | 3.96 | 4.55 |
| EV to Sales | -197.51 | 5.52 | 2.83 | 0.00 | 0.92 |
| EV to Free Cash Flow | -1.29 | 94.17 | -39.11 | -10.60 | 4.92 |
| EV to Operating Cash Flow | -1.24 | 62.28 | -48.76 | 7.62 | 4.54 |
| Tangible Book Value Per Share | -4.37 | 0.04 | 0.05 | 0.02 | 0.02 |
| Shareholders’ Equity Per Share | 0.09 | 0.05 | 0.06 | 0.03 | 0.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.21 | -81.75 | -42.42 | -0.11 | -0.24 |
| Revenue Per Share | 0.14 | 0.08 | 0.06 | 33.72 | 0.03 |
| Net Income Per Share | 0.04 | -0.00 | 0.02 | 4.35 | 0.01 |
| Tax Burden | 0.79 | 82.75 | 43.42 | 1.11 | 1.24 |
| Interest Burden | 1.14 | -0.07 | 0.44 | 781.76 | 1.41 |
| Research & Development to Revenue | 38.58 | 0.09 | 0.12 | 0.18 | 0.13 |
| SG&A to Revenue | 118.20 | 0.11 | 0.12 | 0.15 | 0.14 |
| Stock-Based Compensation to Revenue | 1.19 | 0.00 | 0.15 | 0.00 | 0.02 |
| Income Quality | 0.53 | -1.73 | -0.16 | 0.94 | 0.73 |
Currency in USD

